SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Manhattan, New York USA - July 9, 2011: Pfizer letter sign on the building's Headquarters. Pfizer's is the largest pharmaceutical company in the world.
Business
JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff
Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted a 2028 launch. CEO Albert Bourla explained the pharma’s strategy at J.P. Morgan on Monday.
January 13, 2026
 · 
3 min read
 · 
Nick Paul Taylor
the skyline of san francisco at night
Events
JPM26 Day 1: Obesity Front-and-Center, Q4 Sales Beats
Obesity took center stage on the first day of the 2026 J.P. Morgan Healthcare Conference, with industry frontrunners Eli Lilly and Novo Nordisk providing supply chain, regulatory and pricing updates.
January 13, 2026
 · 
3 min read
 · 
Tristan Manalac
Stairs Leading to Flying Paper Plane - Success, Growth, and Freedom, 3D Render
ADCs
Lung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADC
The FDA initially placed the Phase III IDeate-Lung02 study on hold due to a “higher than expected” number of deaths in patients treated with ifinatamab deruxtecan.
January 13, 2026
 · 
3 min read
 · 
Tristan Manalac
Fashionable halftone collage. Concept of wealth, saving, saving and saving money. Money bag with dollar stacks and stacks of coins. Vector illustration of business and finance for web banner, social media banner, marketing material. Vector illustration
Manufacturing
AbbVie Commits $100B in US R&D, Manufacturing, Winning Tariff, Pricing Exemptions
AbbVie has also pledged to participate in TrumpRx and offer many of its products, including Humira, on a direct-to-patient basis. In exchange, the pharma secured exemptions from tariffs and other future pricing directives.
January 13, 2026
 · 
2 min read
 · 
Tristan Manalac
FDA signage at its headquarters in Maryland
Manufacturing
AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
Drugmakers told the FDA that inflexible post-approval change requirements are among the top regulatory barriers to the reshoring of pharmaceutical manufacturing.
January 13, 2026
 · 
5 min read
 · 
Nick Paul Taylor
abstract image of DNA, tablets and planet earth. 3D-image
Policy
At JPM26, Experts Try To Look Past the Most Favored Nation ‘Distraction’
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
January 12, 2026
 · 
4 min read
 · 
Dan Samorodnitsky
Cartoon tiny people work with scientific equipment, develop innovations, new projects ideas. Startup business teamwork, solution development through science knowledge dark concept vector illustration
Collaboration
JPM26: BMS’s Early-Stage Bets Are Happening Now, Amid Pharma’s Late-Stage Frenzy
Mature biopharma deals are stealing all the headlines, but Bristol Myers Squibb’s Robert Plenge says the company’s deals with insitro, Orbital and more are building the future.
January 12, 2026
 · 
3 min read
 · 
Annalee Armstrong
AbbVie's office in South San Francisco, California
Cancer
AbbVie Bets Nearly $5B on RemeGen To Vie for Position in Hot Bispecific Market
The deal, which sees AbbVie paying RemeGen $650 million upfront, gives the pharma ex-China rights to the biotech’s PD-1/VEGF bispecific antibody—a modality being targeted by companies including BMS, Merck and Pfizer.
January 12, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Cambridge, USA - 16 August 2024. View of Moderna office entrance with logo sign, Biotechnology industry
Business
Moderna Hits 2025 Revenue Goal as Operating Costs Fall Faster than Forecast
While Moderna’s full-year sales landed in the upper end of its target range, Jefferies analysts said further reductions are needed if the biotech hopes to hit its 2028 break-even target.
January 12, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS